新型冠状病毒肺炎对血液肿瘤患者预后及治疗策略的影响  

Impact of Coronavirus Disease 2019 on Prognosis and Treatment Strategies in Patients with Hematological Malignancy——Review

作　　者：冷同爱 杨琛 王利 高春记[3] LENG Tong-Ai;YANG Chen;WANG Li;GAO Chun-Jia(Depariment of Outpatients and EmergencyLaoshan Medical District,NO.971 Hospital of Chinese PLA Navy Qingdao 266101,Shandong Province,China;Depariment of Hemaiology and Oncology,Laoshan Medical District,NO.971 Hospital of Chinese PLA Navy Qingdao 266101,Shandong Province,China;Department of Hematology Chinese PLA General Hospital,Bejing 100853,China)

机构地区：[1]海军第九七一医院崂山医疗区门诊急诊医学科,山东青岛266101 [2]海军第九七一医院崂山医疗区血液肿瘤科,266101 [3]解放军总医院第一医学中心血液科,北京100853

出　　处：《中国实验血液学杂志》2022年第2期645-648,共4页Journal of Experimental Hematology

基　　金：北京市自然科学基金面上项目(7162175);山东省医药卫生科技发展计划项目(2019WSG01004)。

摘　　要：新型冠状病毒肺炎(COVID-19)自暴发以来迅速在境内外蔓延,目前已成为全球公共卫生危机。血液肿瘤患者因基础免疫功能低、放化疗强度大、造血干细胞移植后免疫重建缓慢等原因,一旦感染COVID-19,病情往往较重甚至失去生命,抗感染、输血、粒细胞集落刺激因子使用等治疗策略也需要进行一些调整。疾病特征、化疗、造血干细胞移植等因素均可能影响患者感染COVID-19后的预后。本文将对相关最新研究进展进行综述。Coronavirus disease 2019(COVID-19) has spread rapidly worldwide since outbreak in December 2019, and become a global public health crisis. Patients with hematological malignancy concurrently infected with COVID-19 are often associated with severe even fatal complications, due to low basic immune function, high intensity of chemotherapy and radiotherapy, and slow immune reconstruction post hematopoietic stem cell transplantation, and their treatment strategies, such as anti-infective therapy, blood transfusion, and the use of granulocyte colony stimulating factor need to be adjusted. The characteristics of patients, chemotherapy, hematopoietic stem cell transplantation, and other clinical factors may affect the prognosis of patients with hematological malignancy concurrently infected with COVID-19. Herein, the latest research progress is reviewed.

关 键 词：新型冠状病毒肺炎 血液肿瘤 预后 治疗策略 

分 类 号：R733[医药卫生—肿瘤]